Antibodies to Costimulatory Receptor 4‐1BB Enhance Anti‐tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
Sign Up to like & getrecommendations! Published in 2018 at "Immunity"
DOI: 10.1016/j.immuni.2018.09.014
Abstract: &NA; The costimulatory receptor 4‐1BB is expressed on activated immune cells, including activated T cells. Antibodies targeting 4‐1BB enhance the proliferation and survival of antigen‐stimulated T cells in vitro and promote CD8 T cell‐dependent anti‐tumor… read more here.
Keywords: cell; receptor 1bb; anti 1bb; anti tumor ... See more keywords
CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy
Sign Up to like & getrecommendations! Published in 2019 at "Nature Communications"
DOI: 10.1038/s41467-018-08123-8
Abstract: Agonist antibodies (Ab) directed against costimulatory molecules on the surface of antigen-primed T cells are in various stages of pre-clinical and clinical trials, albeit with limited therapeutic benefit as single agents. The underlying mechanisms of… read more here.
Keywords: anti 1bb; therapy; resistance anti; cd73 expression ... See more keywords
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
Sign Up to like & getrecommendations! Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-002428
Abstract: Background Stimulation of 4-1BB with agonistic antibodies is a promising strategy for improving the therapeutic efficacy of immune checkpoint inhibitors (ICIs) or for overcoming resistance to ICIs. However, dose-dependent hepatotoxicity was observed in clinical trials… read more here.
Keywords: anti 1bb; antibody; anti tumor; bispecific antibody ... See more keywords
Abstract 1721: Diversity evenness of TCR repertoire in the tumor and periphery reflects antitumor activity and immune-related adverse events, respectively
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-1721
Abstract: To develop more effective combination immunotherapies lacking immune-related adverse events, we investigated the nature of the intratumoral immune response and systemic immune response induced by immunotherapies. B16 melanoma cells were subcutaneously inoculated into IFNγ venus… read more here.
Keywords: diversity; anti 1bb; immune related; tcr ... See more keywords
Abstract 5299: A novel anti-4-1BB antibody with no liver toxicity and its application in a bi-specific antibody
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-5299
Abstract: 4-1BB (CD137, TNFRSF9) is a co-stimulatory receptor initially identified on T cells, belonging to the tumor necrosis factor receptor superfamily. Primarily expressed on activated CD8+ T cells, it plays a crucial role in immune activation.… read more here.
Keywords: antibody; anti 1bb; toxicity; tumor ... See more keywords